H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 130 Citations 103,281 504 World Ranking 1000 National Ranking 598

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Internal medicine

His primary areas of study are Cancer research, Imatinib mesylate, Imatinib, Chronic myelogenous leukemia and Leukemia. His Cancer research research incorporates themes from Mutation, Tyrosine kinase, Proto-oncogene tyrosine-protein kinase Src, Receptor tyrosine kinase and K562 cells. He has researched Imatinib mesylate in several fields, including Cytarabine and ABL.

His Imatinib study is concerned with Myeloid leukemia in general. His study on Chronic myelogenous leukemia also encompasses disciplines like

  • Philadelphia chromosome together with Drug resistance,
  • Clinical trial that connect with fields like Pharmacology. His Leukemia research is multidisciplinary, incorporating elements of Myeloid, Regulation of gene expression and Pharmacokinetics.

His most cited work include:

  • Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia (4424 citations)
  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (3544 citations)
  • Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. (3161 citations)

What are the main themes of his work throughout his whole career to date?

Brian J. Druker spends much of his time researching Cancer research, Myeloid leukemia, Imatinib, Leukemia and Imatinib mesylate. His research integrates issues of Tyrosine kinase, ABL, Chronic myelogenous leukemia, Philadelphia chromosome and Kinase in his study of Cancer research. His Myeloid leukemia study combines topics from a wide range of disciplines, such as Myeloid and Progenitor cell, Stem cell.

His Imatinib research integrates issues from Oncology, Tyrosine-kinase inhibitor and Pharmacology. His Leukemia research focuses on Bone marrow and how it relates to Stromal cell. His Imatinib mesylate study frequently links to related topics such as Signal transduction.

He most often published in these fields:

  • Cancer research (72.38%)
  • Myeloid leukemia (42.82%)
  • Imatinib (37.88%)

What were the highlights of his more recent work (between 2016-2021)?

  • Cancer research (72.38%)
  • Myeloid leukemia (42.82%)
  • Leukemia (40.29%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Cancer research, Myeloid leukemia, Leukemia, Internal medicine and Cancer. Brian J. Druker does research in Cancer research, focusing on Imatinib mesylate specifically. His biological study spans a wide range of topics, including Ponatinib and ABL.

Brian J. Druker works in the field of Myeloid leukemia, focusing on Imatinib in particular. His work in Leukemia addresses issues such as Bone marrow, which are connected to fields such as Stromal cell and Tumor microenvironment. While the research belongs to areas of Internal medicine, Brian J. Druker spends his time largely on the problem of Oncology, intersecting his research to questions surrounding Tyrosine-kinase inhibitor, Survival analysis and BET inhibitor.

Between 2016 and 2021, his most popular works were:

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (434 citations)
  • Functional genomic landscape of acute myeloid leukaemia. (288 citations)
  • Functional genomic landscape of acute myeloid leukaemia. (288 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Internal medicine

Brian J. Druker mostly deals with Cancer research, Leukemia, Myeloid leukemia, Myeloid and Internal medicine. His work carried out in the field of Cancer research brings together such families of science as Viability assay, Cell, Cell culture, Kinase and Allosteric regulation. His studies in Leukemia integrate themes in fields like Atypical chronic myeloid leukemia, Ruxolitinib and Tyrosine-kinase inhibitor.

Specifically, his work in Myeloid leukemia is concerned with the study of Imatinib. He studies Imatinib, namely Imatinib mesylate. His Internal medicine study which covers Oncology that intersects with Survival analysis, Clinical trial and Precision medicine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng.
The New England Journal of Medicine (2001)

6767 Citations

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Brian J. Druker;Shu Tamura;Elisabeth Buchdunger;Sayuri Ohno.
Nature Medicine (1996)

6089 Citations

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele.
The New England Journal of Medicine (2002)

5026 Citations

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)

4164 Citations

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)

3961 Citations

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta.
The New England Journal of Medicine (2001)

3592 Citations

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke.
Journal of Clinical Oncology (2003)

2614 Citations

Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

Heikki Joensuu;Peter J. Roberts;Maarit Sarlomo-Rikala;Leif C. Andersson.
The New England Journal of Medicine (2001)

2593 Citations

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot.
The New England Journal of Medicine (2002)

2532 Citations

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Elisabeth Buchdunger;Catherine L. Cioffi;Norman Law;David Stover.
Journal of Pharmacology and Experimental Therapeutics (2000)

1969 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Brian J. Druker

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 480

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 477

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 266

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 193

Michele Baccarani

Michele Baccarani

University of Bologna

Publications: 179

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 177

Giuseppe Saglio

Giuseppe Saglio

University of Turin

Publications: 173

Michael W. Deininger

Michael W. Deininger

Huntsman Cancer Institute

Publications: 165

Giovanni Martinelli

Giovanni Martinelli

University of Bologna

Publications: 160

John M. Goldman

John M. Goldman

Imperial College London

Publications: 150

Michael Heinrich

Michael Heinrich

Oregon Health & Science University

Publications: 143

Srdan Verstovsek

Srdan Verstovsek

The University of Texas MD Anderson Cancer Center

Publications: 140

Jane F. Apperley

Jane F. Apperley

Imperial College London

Publications: 135

Francis J. Giles

Francis J. Giles

National University of Ireland, Galway

Publications: 134

Peter Valent

Peter Valent

Medical University of Vienna

Publications: 128

Moshe Talpaz

Moshe Talpaz

University of Michigan–Ann Arbor

Publications: 126

Something went wrong. Please try again later.